Temlett JA - Search Results

1

Transplantation of embryonic marmoset dopaminergic neurons to the corpus striatum of marmosets rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Fine A, Hunt SP, Oertel WH, Nomoto M, Chong PN, Bond A, Waters C, Temlett JA, Annett L, Dunnett S, et al. Fine A, et al. Among authors: temlett ja. Prog Brain Res. 1988;78:479-89. doi: 10.1016/s0079-6123(08)60321-0. Prog Brain Res. 1988. PMID: 3150110 No abstract available.

2

The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.

Temlett JA, Chong PN, Oertel WH, Jenner P, Marsden CD. Temlett JA, et al. Eur J Pharmacol. 1988 Nov 1;156(2):197-206. doi: 10.1016/0014-2999(88)90322-6. Eur J Pharmacol. 1988. PMID: 2977118

3

The antiparkinsonian activity of CQA 206-291, a new D2 dopamine receptor agonist.

Temlett JA, Quinn NP, Marsden CD, Lataste X, Jaton AL. Temlett JA, et al. Clin Neuropharmacol. 1989 Feb;12(1):55-9. doi: 10.1097/00002826-198902000-00007. Clin Neuropharmacol. 1989. PMID: 2565766

4

A strategy for measuring the therapeutic properties of new antiparkinsonian drugs, such as +PHNO, in patients with on-off fluctuations.

Coleman RJ, Temlett JA, Quinn NP, Stahl SM, Marsden CD. Coleman RJ, et al. Among authors: temlett ja. Clin Neuropharmacol. 1989 Feb;12(1):37-45. doi: 10.1097/00002826-198902000-00005. Clin Neuropharmacol. 1989. PMID: 2565765

5

Selective increase in somatostatin mRNA expression in human basal ganglia in Parkinson's disease.

Eve DJ, Nisbet AP, Kingsbury AE, Temlett J, Marsden CD, Foster OJ. Eve DJ, et al. Brain Res Mol Brain Res. 1997 Oct 15;50(1-2):59-70. doi: 10.1016/s0169-328x(97)00172-1. Brain Res Mol Brain Res. 1997. PMID: 9406918

6

Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.

Temlett JA, Quinn NP, Jenner PG, Marsden CD, Pourcher E, Bonnet AM, Agid Y, Markstein R, Lataste X. Temlett JA, et al. Mov Disord. 1989;4(3):261-5. doi: 10.1002/mds.870040307. Mov Disord. 1989. PMID: 2571082

7

Adjunctive therapy with bromocriptine in Parkinson's disease.

Temlett JA, Ming A, Saling M, Fritz VU, Blumenfeld A, Bilchik TR, Becker AL, Fourie PB, Reef HE. Temlett JA, et al. S Afr Med J. 1990 Dec 1;78(11):680-5. S Afr Med J. 1990. PMID: 2251616 Clinical Trial.

8

Differential release of acetylcholinesterase in vivo, from the guinea pig substantia nigra compared to the caudate putamen following dopamine depletion.

Dally JJ, Temlett JA, Greenfield SA. Dally JJ, et al. Among authors: temlett ja. Neuropharmacology. 1996 May;35(5):579-87. doi: 10.1016/0028-3908(96)84627-2. Neuropharmacology. 1996. PMID: 8887965

9

Sinemet (CR4): an open-label study in moderately severe Parkinson's disease.

Ming A, Temlett JA, Fritz VU. Ming A, et al. Among authors: temlett ja. J Intern Med. 1991 Aug;230(2):113-7. doi: 10.1111/j.1365-2796.1991.tb00417.x. J Intern Med. 1991. PMID: 1865161

10

Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study.

Bruggeman R, van der Linden C, Buitelaar JK, Gericke GS, Hawkridge SM, Temlett JA. Bruggeman R, et al. Among authors: temlett ja. J Clin Psychiatry. 2001 Jan;62(1):50-6. doi: 10.4088/jcp.v62n0111. J Clin Psychiatry. 2001. PMID: 11235929 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters